Fatal hemorrhagic pneumonia in patients with hematologic diseases and Stenotrophomonas maltophilia bacteremia: a retrospective study
Authors:
Open Access
- 31 July 2021
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 21 (1) , 1-10
Abstract
Fatal hemorrhagic pneumonia is one of the most severe manifestations of Stenotrophomonas maltophilia (SM) infections. Here, we aimed to investigate the clinical characteristics of SM bacteremia and to identify the risk factors of hemorrhagic pneumonia caused by SM in patients with hematologic diseases. The clinical records of 55 patients diagnosed with hematologic diseases and SM bacteremia were retrospectively reviewed. We compared patients’ clinical characteristics and outcomes between the hemorrhagic pneumonia group and non-hemorrhagic pneumonia group. Twenty-seven (49.1%) patients developed hemorrhagic pneumonia. The overall mortality rate of SM bacteremia was 67.3%. Hemorrhagic pneumonia (adjusted HR 2.316, 95% CI 1.140–4.705; P = 0.020) was an independent risk factor of 30-day mortality in hematological patients with SM bacteremia. Compared with the non-hemorrhagic pneumonia group, patients in the hemorrhagic pneumonia group were older and showed clinical manifestations as higher proportions of isolated SM in sputum culture, neutropenia and elevated procalcitonin (PCT). Multivariate analysis showed that neutropenia, high levels of PCT, prior tigecycline therapy within 1 month were independent risk factors associated with hemorrhagic pneumonia. Neutropenia, high level of PCT and prior tigecycline therapy within 1 month were significant independent predictors of hemorrhagic pneumonia in hematologic patients with SM bacteremia. Due to no effective antibiotics to prevent hemorrhagic pneumonia, prophylaxis of SM infection and its progression to hemorrhagic pneumonia is particularly important.Keywords
All Related Versions
Funding Information
- Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2017KY059)
This publication has 35 references indexed in Scilit:
- Tigecycline as a therapeutic option inStenotrophomonas maltophiliainfectionsJournal of Chemotherapy, 2012
- Stenotrophomonas maltophilia infection in hematopoietic SCT recipients: high mortality due to pulmonary hemorrhageBone Marrow Transplantation, 2012
- Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancyTransplant Infectious Disease, 2012
- Elevated procalcitonin predicts Gram-negative sepsis in haematological patients with febrile neutropeniaScandinavian Journal of Infectious Diseases, 2011
- CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care settingAmerican Journal of Infection Control, 2008
- Procalcitonin (PCT) and C-reactive Protein (CRP) as severe systemic infection markers in febrile neutropenic adultsBMC Infectious Diseases, 2007
- Impact of Initial Antimicrobial Therapy in Patients with Bloodstream Infections Caused by Stenotrophomonas maltophiliaAntimicrobial Agents and Chemotherapy, 2005
- Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive proteinEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- The Major Extracellular Protease of the Nosocomial Pathogen Stenotrophomonas maltophiliaJournal of Biological Chemistry, 2002
- Bacteremia Due to Stenotrophomonas maltophilia in Patients with Hematologic MalignanciesClinical Infectious Diseases, 2000